Headline News

 

GSK’s Trelegy Ellipta now approved for use in adults with uncontrolled asthma in China

Posted on January 27, 2026

GSK’s Arexvy receives approval in Europe for expanded use in all adults 18 years and older

Posted on January 27, 2026

Sofetabart mipitecan receives breakthrough therapy designation for the treatment of platinum-resistant ovarian cancer

Posted on January 27, 2026

AstraZeneca to complete its direct listing of ordinary shares and US debt securities on the New York Stock Exchange

Posted on January 27, 2026

Sanofi’s amlitelimab highlights its potential in atopic dermatitis

Posted on January 27, 2026

Pimicotinib accepted for the treatment of tenosynovial giant cell tumor by the U.S. FDA

Posted on January 19, 2026

Ianalumab receives FDA breakthrough therapy designation for Sjögren’s disease

Posted on January 19, 2026

AbbVie and RemeGen announce new licensing agreement to develop an antibody for advanced solid tumors

Posted on January 19, 2026

AbbVie releases new results for Epcoritamab from phase 3 EPCORE DLBCL-1 trial in patients with relapsed/refractory diffuse large B-cell lymphoma

Posted on January 19, 2026

Johnson and Johnsons TECVAYLI monotherapy highlights superior survival in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Posted on January 19, 2026

Johnson & Johnson release their new mobile simulator app to support breast augmentation patients

Posted on January 19, 2026

CAPLYTA proven to be as a promising option for achieving remission in adults with major depressive disorder

Posted on January 19, 2026

Bayer’s Eylea 8 mg has officially been approved for third retinal indication in the EU

Posted on January 19, 2026

U.S. Supreme Court decision to review Bayer’s Durnell case in the Roundup litigation

Posted on January 19, 2026

AbbVie releases new results for Epcoritamab in patients with relapsed/refractory diffuse large b-cell lymphoma

Posted on January 19, 2026